AIM - Midatech Pharma PLC Announces Results for the year ended 31 December 2019

Preliminary results for the year ended 31 December 2019

ABINGDON, OXFORDSHIRE / ACCESSWIRE / June 16, 2020 / Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines announces its audited preliminary results for the year ended 31 December 2019.

Financial highlights

• Total gross revenue⁽¹⁾ for the year of £0.7m (2018: £1.9m, 2017: £1.0m).
• Statutory revenue⁽²⁾ for 2019 of £0.3m (2018: £0.1m, 2017: £0.1m).
• Subscription, Placing and Open Offer in February 2019 raised £12.3m (net) and Registered Direct Offering in the US in October 2019 raised $2.5m (£1.8m) (net).
• Receipt of €3.6m (£3.1m) (net) non-dilutive Reindus loan and award of Guazatu loan of €1.5m.
• Provisional award of a GlioKIDS grant of €2.7m (£2.3m), subject to confirmation of Midatech's status as an SME, to support a Phase II trial of MTX110.
• Cash and deposits at 31 December 2019 of £10.9m (2018: £2.3m, 2017: £13.2m).
• Net loss from continuing operations of £9.1m (2018: £10.4m loss, 2017: £11.7m loss) with net cash inflow in the year of £8.4m (2018: £10.9m outflow, 2017: £4.1m outflow).
• Tax credit receivable of £1.8m (2018: £1.9m, 2017: £1.2m).

Click on, or paste the following link into your web browser, to view the full announcement.

http://www.rns-pdf.londonstockexchange.com/rns/0316Q_1-2020-6-15.pdf

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Midatech Pharma PLC